XON - Intrexon Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Intrexon Corporation

20374 Seneca Meadows Parkway
Germantown, MD 20876
United States
301-556-9900
http://www.dna.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees882

Key Executives

NameTitlePayExercisedYear Born
Mr. Randal J. KirkChairman & CEO100kN/A1953
Mr. Rick L. SterlingChief Financial Officer597.47kN/A1964
Mr. Donald P. LehrChief Legal Officer & Corp. Sec.706.23kN/A1975
Dr. Helen Sabzevari MPH, Ph.D.Pres of Precigen, Inc.614.62kN/A1962
Dr. Thomas D. ReedFounder & Chief Science OfficerN/AN/A1966
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Intrexon Corporation engages in the engineering and industrialization of biology in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. It provides reproductive technologies and other genetic processes to cattle breeders and producers; biological insect control solutions; technologies for non-browning apple without the use of artificial additives; genetically engineered swine for medical and genetic research; commercial aquaculture products; and preservation and cloning technologies. The company also offers UltraVector platform that enables design and assembly of gene programs that facilitate control over the quality, function, and performance of living cells; and RheoSwitch inducible gene switch that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression. In addition, it provides AttSite Recombinases, which allows stable, targeted gene integration and expression; LEAP automated platform to identify and purify cells of interest, such as antibody expressing cells and stem cells; ActoBiotics platform for targeted in situ expression of proteins and peptides from engineered microbes; and AdenoVerse technology platform for tissue specificity and target selection. The company serves the health, food, energy, and environment markets. Intrexon Corporation has collaboration and license agreements with ZIOPHARM Oncology, Inc.; Ares Trading S.A.; Oragenics, Inc.; Intrexon T1D Partners, LLC; Intrexon Energy Partners, LLC; Intrexon Energy Partners II, LLC; Genopaver, LLC; Fibrocell Science, Inc.; Persea Bio, LLC; OvaXon, LLC; S & I Ophthalmic, LLC; Harvest start-up entities; and Surterra Wellness. The company was formerly known as Genomatix Ltd. and changed its name to Intrexon Corporation in 2005. Intrexon Corporation was founded in 1998 and is based in Germantown, Maryland.

Corporate Governance

Intrexon Corporation’s ISS Governance QualityScore as of October 4, 2019 is 7. The pillar scores are Audit: 10; Board: 6; Shareholder Rights: 2; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.